参考文献/References:
[1] Penna S,Villa A,Capo V.Autosomal recessive osteopetrosis: mechanisms and treatments[J].Dis Model Mech,2021,14(5):dmm048940.DOI:10.1242/dmm.048940.
[2] Stark Z,Savarirayan R.Osteopetrosis[J].Orphanet J Rare Dis,2009,4:5. DOI:10.1186/1750-1172-4-5.
[3] Kim JM,Lin C,Stavre Z,et al.Osteoblast-osteoclast communication and bone homeostasis[J].Cells,2020,9(9):2073.DOI:10.3390/cells9092073.
[4] Charoenngam N,Cevik MB,Holick MF.Diagnosis and management of pediatric metabolic bone diseases associated with skeletal fragility[J].Curr Opin Pediatr,2020,32(4):560-573.DOI:10.1097/MOP.0000000000000914.
[5] Teti A,Econs MJ.Osteopetroses,emphasizing potential approaches to treatment[J].Bone,2017,102:50-59.DOI:10.1016/j.bone.2017.02.002.
[6] Gregson CL,Duncan EL.The genetic architecture of high bone mass[J].Front Endocrinol(Lausanne),2020,11:595653. DOI:10.3389/fendo.2020.595653.
[7] Shaik NA,Bokhari HA,Masoodi TA,et al.Molecular modelling and dynamics of CA2 missense mutations causative to carbonic anhydrase 2 deficiency syndrome[J].J Biomol Struct Dyn,2020,38(14):4067-4080.DOI:10.1080/07391102.2019.1671899.
[8] Li L,Lv SS,Wang C,et al.Novel CLCN7 mutations cause autosomal dominant osteopetrosis type II and intermediate autosomal recessive osteopetrosis[J].Mol Med Rep,2019,19(6):5030-5038.DOI:10.3892/mmr.2019.10123.
[9] Wu CC,Econs MJ,DiMeglio LA,et al.Diagnosis and Management of Osteopetrosis:Consensus Guidelines From the Osteopetrosis Working Group[J].J Clin Endocrinol Metab,2017,102(9):3111-3123.DOI:10.1210/jc.2017-01127.
[10] Stepensky P,Grisariu S,Avni B,et al.Stem cell transplantation for osteopetrosis in patients beyond the age of 5 years[J].Blood Adv,2019,3(6):862-868.DOI:10.1182/bloodadvances.2018025890.
[11] Capo V,Penna S,Merelli I,et al.Expanded circulating hematopoietic stem/progenitor cells as novel cell source for the treatment of TCIRG1 osteopetrosis[J].Haematologica,2021,106(1):74-86.DOI:10.3324/haematol.2019.238261.
[12] Sabir AH,Cole T.The evolving therapeutic landscape of genetic skeletal disorders[J].Orphanet J Rare Dis,2019,14(1):300.DOI:10.1186/s13023-019-1222-2.
[13] Jensen TL,Gøtzsche CR,Woldbye DPD.Current and future prospects for gene therapy for rare genetic diseases affecting the brain and spinal cord[J].Front Mol Neurosci,2021,14:695937.DOI:10.3389/fnmol.2021.695937.
[14] Moscatelli I,Almarza E,Schambach A,et al.Gene therapy for infantile malignant osteopetrosis:review of pre-clinical research and proof-of-concept for phenotypic reversal[J].Mol Ther Methods Clin Dev,2020,20:389-397.DOI:10.1016/j.omtm.2020.12.009.
[15] Moscatelli I,Löfvall H,Schneider Thudium C,et al.Targeting NSG mice engrafting cells with a clinically applicable lentiviral vector corrects osteoclasts in infantile malignant osteopetrosis[J].Hum Gene Ther,2018,29(8):938-949.DOI:10.1089/hum.2017.053.
[16] Löfvall H,Rothe M,Schambach A,et al.Hematopoietic stem cell-targeted neonatal gene therapy with a clinically applicable lentiviral vector corrects osteopetrosis in oc/oc mice[J].Hum Gene Ther,2019,30(11):1395-1404.DOI:10.1089/hum.2019.047.
[17] Okur FV,Cevher ,Özdemir C,et al.Osteopetrotic induced pluripotent stem cells derived from patients with different disease-associated mutations by non-integrating reprogramming methods[J].Stem Cell Res Ther,2019,10(1):211.DOI:10.1186/s13287-019-1316-8.
[18] Hennig AF,Rössler U,Boiti F,et al.Generation of a human induced pluripotent stem cell line(BIHi002-A)from a patient with CLCN7-related infantile malignant autosomal recessive osteopetrosis[J].Stem Cell Res,2019,35:101367.DOI:10.1016/j.scr.2018.101367.
[19] Chen W,Twaroski K,Eide C,et al.TCIRG1 transgenic rescue of osteoclast function using induced pluripotent stem cells derived from patients with infantile malignant autosomal recessive osteopetrosis[J].J Bone Joint Surg Am,2019,101(21):1939-1947.DOI:10.2106/JBJS.19.00558.
[20] Maurizi A,Capulli M,Patel R,et al.RNA interference therapy for autosomal dominant osteopetrosis type 2.Towards the preclinical development[J].Bone,2018,110:343-345.DOI:10.1016/j.bone.2018.02.031.
相似文献/References:
[1]孙敏讷,段宇.老年亚临床甲状腺功能减退症的诊治特点[J].国际内分泌代谢杂志,2014,(06):411.[doi:10.3760/cma.j.issn.1673-4157.2014.06.014]
Sun Minne,Duan Yu..Diagnositc and therapeutic characteristics of subclinical hypothyroidism in elderly people[J].International Journal of Endocrinology and Metabolism,2014,(04):411.[doi:10.3760/cma.j.issn.1673-4157.2014.06.014]
[2]胡欣 陈国芳 刘超.男性迟发型性腺功能减退症的诊断与治疗[J].国际内分泌代谢杂志,2015,(01):59.[doi:10.3760/cma.j.issn.1673-4157.2015.01.015]
Hu Xin,Chen Guofang,Liu Chao..Diagnosis and therapeutic options for late-onset hypogonadism in men[J].International Journal of Endocrinology and Metabolism,2015,(04):59.[doi:10.3760/cma.j.issn.1673-4157.2015.01.015]
[3]刘晓蓉 朱德发.糖尿病下肢动脉病变的诊断与治疗[J].国际内分泌代谢杂志,2015,(05):327.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.010]
Liu Xiaorong*,Zhu Defa..Diagnosis and treatment of lower extremity arterial disease in diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2015,(04):327.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.010]
[4]曹琳,刘超.妊娠糖尿病诊疗的争议与共识[J].国际内分泌代谢杂志,2016,36(03):176.[doi:10.3760/cma.j.issn.1673-4157.2016.03.08]
Cao Lin,Liu Chao..Controversy and concensus on the diagnosis and treatment of gestational diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2016,36(04):176.[doi:10.3760/cma.j.issn.1673-4157.2016.03.08]
[5]毛斐,鹿斌,李益明.SUDOSCAN对糖尿病周围神经病变的诊断价值[J].国际内分泌代谢杂志,2016,36(05):331.[doi:10.3760/cma.j.issn.1673-4157.2016.05.12]
Mao Fei,Lu Bin,Li Yiming.Diagnostic value of SUDOSCAN in detecting diabetic peripheral neuropathy[J].International Journal of Endocrinology and Metabolism,2016,36(04):331.[doi:10.3760/cma.j.issn.1673-4157.2016.05.12]
[6]郑仁东,刘超.糖尿病合并男性性腺功能减退症的识别与处理[J].国际内分泌代谢杂志,2016,36(06):394.[doi:10.3760/cma.j.issn.1673-4157.2016.06.09]
Zheng Rendong,Liu Chao..Recognition and treatment of diabetes with male hypogonadism[J].International Journal of Endocrinology and Metabolism,2016,36(04):394.[doi:10.3760/cma.j.issn.1673-4157.2016.06.09]
[7]刘颖丰,刘芳.角膜共聚焦显微镜对糖尿病周围神经病变的诊断价值[J].国际内分泌代谢杂志,2017,37(03):178.[doi:10.3760/cma.j.issn.1673-4157.2017.03.009]
Liu Yingfeng,Liu Fang..Diagnostic value of corneal confocal microscopy on diabetic peripheral neuropathy[J].International Journal of Endocrinology and Metabolism,2017,37(04):178.[doi:10.3760/cma.j.issn.1673-4157.2017.03.009]
[8]曹白露,邵加庆.SUDOSCAN在糖尿病微血管并发症早期诊断
及治疗评估中的作用[J].国际内分泌代谢杂志,2017,37(06):401.
Cao Bailu,Shao Jiaqing..The value of SUDOSCAN in the early diagnosis and evaluation of diabetic microvascular complications[J].International Journal of Endocrinology and Metabolism,2017,37(04):401.
[9]赵万霞 王何婷 任月秋 崔景秋.糖尿病肾病早期标志物研究新进展[J].国际内分泌代谢杂志,2018,38(03):192.[doi:10.3760/cma.j.issn.1673-4157.2018.03.012]
Zhao Wanxia*,Wang Heting,Ren Yueqiu,et al.Recent progress on the study of early marker for diabetic nephrophy[J].International Journal of Endocrinology and Metabolism,2018,38(04):192.[doi:10.3760/cma.j.issn.1673-4157.2018.03.012]
[10]邹梦晨 胡萍 罗祥蓉 蒋娅 高方 曹瑛.糖尿病足骨髓炎的诊疗进展[J].国际内分泌代谢杂志,2018,38(04):257.[doi:10.3760/cma.j.issn.1673-4157.2018.04.010]
Zou Mengchen,Hu Ping,Luo Xiangrong,et al.Diagnosis and treatment of diabetic foot osteomyelitis[J].International Journal of Endocrinology and Metabolism,2018,38(04):257.[doi:10.3760/cma.j.issn.1673-4157.2018.04.010]